CovidChloroV1, Main, Corpus, bibRecord, 001964

Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.

Identifieur interne : 001964 ( Main/Corpus ); précédent : 001963; suivant : 001965

Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.

Auteurs : Catherine E. Oldenburg ; Thuy Doan

Source :

The American journal of tropical medicine and hygiene [ 1476-1645 ] ; 2020.

RBID : pubmed:32297590

English descriptors

KwdEn :
- Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (pathogenicity), COVID-19 (MeSH), COVID-19 Testing (MeSH), Clinical Laboratory Techniques (standards), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Drug Repositioning (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Lopinavir (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Practice Guidelines as Topic (MeSH), Randomized Controlled Trials as Topic (standards), Ritonavir (therapeutic use), SARS-CoV-2 (MeSH), Sample Size (MeSH), United States (epidemiology).
MESH :
- chemical , therapeutic use : Antiviral Agents, Azithromycin, Hydroxychloroquine, Lopinavir, Ritonavir.
- geographic , epidemiology : United States.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- standards : Clinical Laboratory Techniques, Randomized Controlled Trials as Topic.
- COVID-19, COVID-19 Testing, Drug Repositioning, Humans, Pandemics, Practice Guidelines as Topic, SARS-CoV-2, Sample Size.

DOI: 10.4269/ajtmh.20-0262
PubMed: 32297590
PubMed Central: PMC7253099

Links to Exploration step

pubmed:32297590

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.</title>
<author><name sortKey="Oldenburg, Catherine E" sort="Oldenburg, Catherine E" uniqKey="Oldenburg C" first="Catherine E" last="Oldenburg">Catherine E. Oldenburg</name>
<affiliation><nlm:affiliation>Department of Ophthalmology, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Doan, Thuy" sort="Doan, Thuy" uniqKey="Doan T" first="Thuy" last="Doan">Thuy Doan</name>
<affiliation><nlm:affiliation>Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Ophthalmology, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32297590</idno>
<idno type="pmid">32297590</idno>
<idno type="doi">10.4269/ajtmh.20-0262</idno>
<idno type="pmc">PMC7253099</idno>
<idno type="wicri:Area/Main/Corpus">001964</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001964</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.</title>
<author><name sortKey="Oldenburg, Catherine E" sort="Oldenburg, Catherine E" uniqKey="Oldenburg C" first="Catherine E" last="Oldenburg">Catherine E. Oldenburg</name>
<affiliation><nlm:affiliation>Department of Ophthalmology, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Doan, Thuy" sort="Doan, Thuy" uniqKey="Doan T" first="Thuy" last="Doan">Thuy Doan</name>
<affiliation><nlm:affiliation>Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Ophthalmology, University of California, San Francisco, San Francisco, California.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">The American journal of tropical medicine and hygiene</title>
<idno type="eISSN">1476-1645</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>COVID-19 (MeSH)</term>
<term>COVID-19 Testing (MeSH)</term>
<term>Clinical Laboratory Techniques (standards)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Lopinavir (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Practice Guidelines as Topic (MeSH)</term>
<term>Randomized Controlled Trials as Topic (standards)</term>
<term>Ritonavir (therapeutic use)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Sample Size (MeSH)</term>
<term>United States (epidemiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Clinical Laboratory Techniques</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>COVID-19 Testing</term>
<term>Drug Repositioning</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Practice Guidelines as Topic</term>
<term>SARS-CoV-2</term>
<term>Sample Size</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32297590</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>04</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-1645</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>102</Volume>
<Issue>6</Issue>
<PubDate><Year>2020</Year>
<Month>06</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of tropical medicine and hygiene</Title>
<ISOAbbreviation>Am J Trop Med Hyg</ISOAbbreviation>
</Journal>
<ArticleTitle>Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>1154-1155</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4269/ajtmh.20-0262</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oldenburg</LastName>
<ForeName>Catherine E</ForeName>
<Initials>CE</Initials>
<AffiliationInfo><Affiliation>Department of Ophthalmology, University of California, San Francisco, San Francisco, California.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Doan</LastName>
<ForeName>Thuy</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Ophthalmology, University of California, San Francisco, San Francisco, California.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Am J Trop Med Hyg</MedlineTA>
<NlmUniqueID>0370507</NlmUniqueID>
<ISSNLinking>0002-9637</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019411" MajorTopicYN="N">Clinical Laboratory Techniques</DescriptorName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
<QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32297590</ArticleId>
<ArticleId IdType="doi">10.4269/ajtmh.20-0262</ArticleId>
<ArticleId IdType="pmc">PMC7253099</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Korean Med Sci. 2020 Feb 24;35(7):e89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32080993</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Trials. 2016 Feb;13(1):22-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26768569</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet HIV. 2018 Mar;5(3):e116-e125</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29199100</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001964 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001964 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32297590
   |texte=   Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32297590" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.

Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki